Kjell Mortier | Fund Manager, Novalis Biotech
Kjell Mortier (Pharm., PhD) is Fund Manager for Novalis Biotech Incubation.
Prior to working for Novalis, Kjell acquired approximately 20-years experience in the biotech industry working in various scientific roles. At Ablynx, now part of Sanofi, he was responsible for the bioanalytical and immunogenicity part of dedicated clinical programs. At Eurofins, a leading CRO in the pharma, food and environmental industry, he supported the CMC-analytical part for various customers in the pharma industry.
Kjell also obtained certification for financial analysis at EHSAL Management school.
Jarislav Belotserkovsky | Investment Manager, Novalis Biotech
Novalis Biotech is an early stage venture capital investor in life sciences.
Our investment focus is “enabling technologies” in life sciences. We strongly believe in capital light platform technology and close interaction with customers already early in the life of the company. Focus areas are: innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health.
We focus on early-stage start-ups, from (pre-)seed stage to series A, and support their evolution by providing funding, sharing our professional and academic connections, and help to shape the business strategy in order to create value for all stakeholders. Read more: https://noval.is/
Powered by: Hyphen Projects | Let's connect: |
Book a ticket
| |||
FAQ Contact Us Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
|
Keep me informed
Download our event app
|
© Copyright 2025 by Hyphen Projects